Wellmarker Bio
Seoul
About Wellmarker Bio
Their Company has developed a biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center. Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developing new drugs that overcome resistance of existing therapeutic approaches. Additionally they are focusing on developing first-in-class biomarker-based drugs for medical unmet needs in various cancers such as colon cancer, lung cancer and liver cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $11.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2021)
- Website: wmbio.co
- Phone: +82-2-6952-1631
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/wellmarker-bio-26399 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.